This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XLRN Acceleron Pharma (XLRN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acceleron Pharma Stock (NASDAQ:XLRN) 30 days 90 days 365 days Advanced Chart Get Acceleron Pharma alerts:Sign Up Key Stats Today's Range$178.75▼$178.7550-Day Range$172.08▼$179.6852-Week Range$108.82▼$189.99VolumeN/AAverage Volume572,759 shsMarket Capitalization$10.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.Read More… Receive XLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XLRN Stock News HeadlinesUK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma DealJanuary 2, 2025 | benzinga.comAcceleron Banks on Muons for Colder FusionDecember 6, 2024 | msn.comElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 23, 2025 | Colonial Metals (Ad)Acceleron Fusion has raised $15M to take a stab at colder fusion, filing revealsOctober 5, 2024 | techcrunch.comAcceleron Fusion has raised $15M to take another stab at cold fusion, filing revealsOctober 1, 2024 | yahoo.comORBIMED CAPITAL GP II LLC's Net WorthFebruary 27, 2024 | benzinga.comXLRN Historical DataOctober 20, 2023 | investing.comBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyApril 15, 2023 | thestreet.comSee More Headlines XLRN Stock Analysis - Frequently Asked Questions How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc. (NASDAQ:XLRN) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.18. The firm's quarterly revenue was up 51.6% compared to the same quarter last year. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX). Company Calendar Last Earnings11/04/2021Today4/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XLRN CIK1280600 Webwww.acceleronpharma.com Phone(617) 649-9200Fax617-649-9988Employees312Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,030,000.00 Net Margins-226.01% Pretax Margin-225.99% Return on Equity-32.11% Return on Assets-29.45% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$92.52 million Price / Sales118.15 Cash FlowN/A Price / Cash FlowN/A Book Value$11.74 per share Price / Book15.23Miscellaneous Outstanding Shares61,156,000Free Float60,116,000Market Cap$10.93 billion OptionableOptionable Beta0.13 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:XLRN) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acceleron Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acceleron Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
